Pharmacokinetic parameters | Estimate (RSE%) | 95% CI |
---|---|---|
Structural parameters | Â | Â |
k10 (h−1) | 0.253 (5.2%) | 0.229–0.281 |
k12 (h−1) | 0.0105 (9.2%) | 0.00878–0.0125 |
 Tumor volume on k12a | 0.0910 (30.0%) | 0.0350–0.544 |
k21 (h−1) | 0.0629 (6.3%) | 0.0555–0.0715 |
k13 (h−1) | 0.0321 (6.9%) | 0.0281–0.0368 |
k31 (h−1) | 0.0625 (5.4%) | 0.0561–0.0689 |
k14 (h−1) | 0.00967 (9.9%) | 0.00807–0.0117 |
 Tumor volume on k14a | 1.08 (7.5%) | 0.921–1.24 |
 Cycle 2 on k14b | 0.731 (8.1%) | 0.619–0.857 |
 Cycle 3 on k14b | 0.498 (11.3%) | 0.407–0.624 |
 Cycle 4–7 on k14b | 0.436 (11.6%) | 0.350–0.544 |
k41 (h−1) | 0.0150 (3.4%) | 0.0141–0.0161 |
k15 (h−1) | 0.275 (6.8%) | 0.240–0.314 |
k51 (h−1) | 0.0247 (6.5%) | 0.0216–0.279 |
BMAX compartment 2 (MBq) | 134 (15.5%) | 100–183 |
V1 (L) | 10.3c | Â |
Inter-individual variability | Â | Â |
k10 (CV%) | 33.1 (18.5%) | 27.6–39.7 |
k13 (CV%) | 33.4 (22.2%) | 26.8–40.8 |
k14 (CV%) | 63.4 (18.9%) | 52.0–75.1 |
k15 (CV%) | 29.1 (35.5%) | 20.2–40.0 |
BMAX compartment 2 (CV%) | 67.0 (36.1%) | 49.1–94.2 |
Inter-occasion variability | Â | Â |
k14 (CV%) | 37.8 (16.5%) | 31.5–44.1 |
Residual unexplained variability | Â | Â |
Proportional error compartment 1 (CV%) | 55.5 (29.0%) | 39.0–71.6 |
Additive error compartment 1 (MBq/L) | 9.57 (16.8%) | 8.02–11.2 |
Proportional error compartment 2 (CV%) | 39.7 (8.6%) | 36.7–43.2 |
Proportional error compartment 3 (CV%) | 31.9 (8.5%) | 29.4–34.6 |
Proportional error compartment 4 (CV%) | 32.7 (9.7%) | 30.0–36.2 |